Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
47781-0485-28 47781-0485 Lenalidomide LENALIDOMIDE 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 3, 2022 In Use
47781-0483-28 47781-0483 Lenalidomide LENALIDOMIDE 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
50242-0177-01 50242-0177 Mosunetuzumab Lunsumio Velo 5.0 mg/.5mL Immunotherapy Bispecific Antibody CD20, CD3 Subcutaneous Dec 19, 2025 In Use
42238-0111-01 42238-0111 Interferon gamma-1b Actimmune 100.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Dec 1, 2013 Jan 17, 2018 No Longer Used
47781-0488-77 47781-0488 Lenalidomide LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 3, 2022 In Use
72606-0012-01 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
57894-0515-01 57894-0515 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 2400.0 mg/15mL, 30000.0 mg/15mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
50242-0918-86 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Mar 8, 2019 Mar 18, 2019 In Use
59651-0345-01 59651-0345 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
63850-0132-01 63850-0132 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Nov 1, 2025 In Use
60505-4537-01 60505-4537 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 Mar 8, 2023 In Use
55513-0326-21 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 21, 2025 In Use
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
73043-0038-28 73043-0038 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
59651-0196-21 59651-0196 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Oct 30, 2020 In Use
00480-1246-21 00480-1246 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2022 In Use
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Mar 26, 2021 In Use
00310-4535-30 00310-4535 Tremelimumab IMJUDO 300.0 mg/15mL Immunotherapy Monoclonal Antibody CTLA-4 Intravenous Oct 21, 2022 In Use
82293-0011-10 82293-0011 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 6, 2026 In Use
43598-0511-01 43598-0511 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
50242-0077-01 50242-0077 Trastuzumab and Hyaluronidase-oysk Herceptin Hylecta 10000.0 U/5mL, 10000.0 U/5mL, 600.0 mg/5mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous Feb 28, 2019 In Use
70771-1680-08 70771-1680 LENALIDOMIDE LENALIDOMIDE 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 7, 2023 In Use
65219-0670-01 65219-0670 Denosumab BOMYNTRA 70.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 30, 2025 In Use
00002-7190-01 00002-7190 Olaratumab Lartruvo 10.0 mg/mL Immunotherapy Monoclonal Antibody PDGFR Intravenous Feb 14, 2017 Nov 27, 2020 No Longer Used
70771-1679-08 70771-1679 LENALIDOMIDE LENALIDOMIDE 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 12, 2022 In Use

Found 12250 results — Export these results